Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M, Mitsikostas DD, Ramirez Campos V, Barash S, Ning X, Diener HC. Ashina M, et al. Among authors: ning x. Headache. 2023 Nov-Dec;63(10):1351-1358. doi: 10.1111/head.14651. Epub 2023 Nov 13. Headache. 2023. PMID: 37955395 Clinical Trial.
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Ferrari MD, et al. Among authors: ning x. Lancet. 2019 Sep 21;394(10203):1030-1040. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16. Lancet. 2019. PMID: 31427046 Clinical Trial.
Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, Gutman D, Rasamoelisolo M, Hallak H, Loupe P, Kessler Y, Ning X, Levi M, Ahn AH, Rabinovich-Guilatt L. Cohen-Barak O, et al. Among authors: ning x. Cephalalgia. 2021 Sep;41(10):1065-1074. doi: 10.1177/03331024211007789. Epub 2021 May 17. Cephalalgia. 2021. PMID: 34000848 Clinical Trial.
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC. Ashina M, et al. Among authors: ning x. J Headache Pain. 2021 Jul 10;22(1):68. doi: 10.1186/s10194-021-01279-7. J Headache Pain. 2021. PMID: 34246226 Free PMC article. Clinical Trial.
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N. Sakai F, et al. Among authors: ning x. Headache. 2021 Jul;61(7):1102-1111. doi: 10.1111/head.14178. Epub 2021 Jul 29. Headache. 2021. PMID: 34323290 Free PMC article. Clinical Trial.
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N. Sakai F, et al. Among authors: ning x. Headache. 2021 Jul;61(7):1092-1101. doi: 10.1111/head.14169. Epub 2021 Jul 29. Headache. 2021. PMID: 34324700 Free PMC article. Clinical Trial.
1,916 results